Dawson James initiated coverage on Affymax (NASDAQ: AFFY ) with a Market Outperform rating and a $32 price target. Dawson James commented, "Commercialization of new products is always tricky, especially in the current environment; however, we believe Omontys is an ideal product for the dialysis market given the new